ExpressionEdits in Cambridge has clinched unspecified riches from global pharmaceutical company Boehringer Ingelheim through ...
ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
The increasing demand for gene therapy and CRISPR technology increases the genome engineering.Dublin, Feb. 12, 2025 (GLOBE ...
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...
Parasites are an often-overlooked threat in pet care, especially for cats, as infestations can cause serious health issues ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Shares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback